China has approved 16 nationally-made Covid-19 vaccines for clinical trials, six of which have entered Phase 3, according to the latest data from the National Medical Products Administration.
Two inactivated Covid-19 vaccines from China have been placed on the conditional market: a vaccine from the China National Biotec Group affiliated with Sinopharm, and the CoronaVac vaccine developed by Sinovac Biotech. They received their respective approvals from the administration on December 30, 2020 and February 5 this year, Xinhua News Agency reported.
In addition to inactivated vaccines, China has adopted four technological approaches for Covid-19 vaccines: recombinant protein vaccines, adenovirus vector vaccines, nucleic acid vaccines, and vaccines using attenuated influenza viruses as vectors.
As of February 9, China had administered 40.52 million doses of the Covid-19 vaccine to key groups, National Health Commission spokesman Mi Feng said at a press conference.
int / pgh
(Only the title and image of this report may have been reworked by Business Standard staff; the rest of the content is automatically generated from a syndicated feed.)
Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting-edge commentary on relevant current issues.
However, we have a demand.
As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.